Craneware (LSE:CRW)
Craneware is a specialist in software for healthcare billing, auditing, 'Chargemaster' management and medicare compliance.
About
Last updated 23-10-2020, 05:54:08pm BSTRelated Articles
-
Look to the future! I’d buy these AIM stocks today
AIM stocks are often risky investments, but they can also see tremendous gains. One Fool looks at his top picks within the AIM market.... Read More »
-
£3k to invest? I’d buy these small-cap stocks in an ISA to retire in comfort
Looking to build a nest egg with your Stocks and Shares ISA? Paul Summers thinks these market minnows could help improve your returns. Read More »
-
3 highly-valued growth stocks I’d watch out for in September
Paul Summers takes a look at three (former) market darlings, all of whom report numbers next month. Read More »
-
Are Costain and Craneware falling knives to catch after 30%+ crashes?
Roland Head gives his view on today's profit warnings from Cranweware plc (LON: CRW) and Costain Group plc (LON: COST). Read More »
-
One Brexit-proof stock that I’d buy today
Read this to find out why I think this AIM stock could deliver impressive returns. Read More »
-
The Boohoo share price has fallen 20% in 2018. Will it bounce back in 2019?
Boohoo Group plc (LON:BOO) shares have fallen on fears of a retail slowdown. Roland Head asks if investors should be buying. Read More »
-
This top growth stock has turned £5,000 into over £27,500 in just 5 years
Can this multi-bagging stock continue to perform? Paul Summers wouldn't bet against it. Read More »
-
2 high-flying growth stocks I’d consider buying for the long term
Expensive they may be but these growth stocks could be great buys for the long term, thinks Paul Summers. Read More »
-
Why I’d ditch plummeting Boohoo.com plc for this fast-rising growth star
Even after dropping over 25% in the past half-year, Boohoo.com plc (LON: BOO) still looks expensive compared to this under-the-radar growth star. Read More »
-
A soaring growth stock I’d buy ahead of Fevertree Drinks plc
Fevertree Drinks plc (LON: FEVR) shares have soared, but is this growth stock set to overtake them? Read More »